Cepheid s Q1 Revenues Grow 3 Percent As Net Loss Widens | GenomeWeb

NEW YORK, May 5 (GenomeWeb News) – Cepheid announced yesterday that its Q1 revenues increased 3 percent to $20.2 million from $19.6 million during the year-ago period, while its net loss grew 9.3 percent to $6.7 million from $3.5 million during the first quarter of 2005. Research and development costs grew 2.9 percent to $5.8 million from $4.5 million during the first quarter of 2005. As of March 31, Cepheid had $59.7 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.